Pancreatic Cancer Research

ResearcherUniversity of VeronaActive in the last 2 years

Anthony James Gill

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-9447-1967; OpenAlex author ID A5032567530, A5143786028. Sources: OpenAlex.

Their work

Papers
76 (first author 2, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
202
Papers, trials and grants by year

2012: 3 papers · 2013: 1 paper · 2014: 7 papers · 2015: 5 papers · 2016: 3 papers · 2017: 4 papers · 2018: 4 papers · 2019: 1 paper · 2020: 8 papers · 2021: 8 papers · 2022: 8 papers · 2023: 4 papers · 2024: 6 papers · 2025: 9 papers · 2026: 5 papers

Papers 50 of 76

  1. Five-year psychological impact and surveillance compliance in the Australian Pancreatic Cancer Screening Program. Co-author DOI 10.1007/s10689-026-00557-0↗
  2. HSP47 is a potential dual cell target and prognostic factor in pancreatic cancer. Co-author DOI 10.1038/s41388-026-03865-y↗
  3. βIII-tubulin can act as a brake on extrinsic apoptosis in pancreatic cancer. Co-author DOI 10.1038/s41419-026-08657-6↗
  4. Validation of the PANAMA Score in Patients With Pancreatic Ductal Adenocarcinoma Undergoing Distal Pancreatectomy. Co-author DOI 10.1111/ans.70999↗
  5. Pulsed priming with the FAK inhibitor narmafotinib enhances both gemcitabine/Abraxane and FOLFIRINOX chemotherapy response in pancreatic cancer Co-author DOI 10.64898/2026.07.23.740234↗
  6. FXYD3 Is Frequently Expressed in Pancreatic Ductal Adenocarcinoma but Does Not Predict Survival. Co-author DOI 10.1002/cam4.70500↗
  7. Mucinous cystic neoplasms and simple mucinous cysts are two distinct precursors of pancreatic cancer: clinicopathological, genomic, and transcriptomic characte… Co-author DOI 10.1002/path.6437↗
  8. Overcoming therapy resistance in pancreatic cancer: challenges and emerging strategies. Co-author DOI 10.1016/j.addr.2025.115647↗
  9. MYH knockdown in pancreatic cancer cells creates an exploitable DNA repair vulnerability. Co-author DOI 10.1016/j.neo.2025.101138↗
  10. Long-term Outcomes Following Resection of Adenocarcinoma Arising from Intraductal Papillary Mucinous Neoplasm (A-IPMN) Versus Pancreatic Ductal Adenocarcinoma … Co-author DOI 10.1097/sla.0000000000006272↗
  11. Promising biomarker panel to monitor therapeutic efficacy of neoadjuvant chemotherapy in pancreatic cancer patients. Co-author DOI 10.1111/eci.14341↗
  12. Total lesion glycolysis is a promising predictor of chemo-response in pancreatic cancer patients treated with neoadjuvant chemotherapy prior to surgery. Co-author DOI 10.1111/eci.70046↗
  13. Targeting the NPY/NPY1R signaling axis in mutant p53-dependent pancreatic cancer impairs metastasis. Co-author DOI 10.1126/sciadv.adq4416↗
  14. Mapping the Proteomic Landscape of Pancreatic Cancer: Prognostic Insights and Subtype Stratification. Co-author DOI 10.1158/2767-9764.crc-25-0229↗
  15. Gene Expression Profiling of Pancreatic Ductal Adenocarcinoma Arising From Intraductal Papillary Mucinous Neoplasms of the Pancreas. Co-author DOI 10.1002/cam4.70499↗
  16. Novel serum protein biomarker panel for early diagnosis of pancreatic cancer. Co-author DOI 10.1002/ijc.34928↗
  17. Fibroblast Activation Protein Is Overexpressed on Both Stromal and Epithelial Cells Before Pancreatic Ductal Adenocarcinoma: Implications for Early Diagnosis o… Co-author DOI 10.1053/j.gastro.2024.06.033↗
  18. Artificial Intelligence-based Segmentation of Residual Pancreatic Cancer in Resection Specimens Following Neoadjuvant Treatment (ISGPP-2): International Improv… Co-author DOI 10.1097/pas.0000000000002270↗
  19. Serum and tissue metallome of pancreatic ductal adenocarcinoma. Co-author DOI 10.1111/cas.16124↗
  20. Temporally resolved proteomics identifies nidogen-2 as a cotarget in pancreatic cancer that modulates fibrosis and therapy response. Co-author DOI 10.1126/sciadv.adl1197↗
  21. Heterogeneous tumor microenvironment in pancreatic ductal adenocarcinoma: An emerging role of single-cell analysis. Co-author DOI 10.1002/cam4.6407↗
  22. A first-in-class pan-lysyl oxidase inhibitor impairs stromal remodeling and enhances gemcitabine response and survival in pancreatic cancer. Co-author DOI 10.1038/s43018-023-00614-y↗
  23. The Impact of Molecular Subtyping on Pathological Staging of Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000005050↗
  24. The Prognostic and Predictive Role of the Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Lymphocyte-to-Monocyte Ratio (LMR) as B… Co-author DOI 10.3390/jcm12051989↗
  25. Neoantigen quality predicts immunoediting in survivors of pancreatic cancer. Co-author DOI 10.1038/s41586-022-04735-9↗
  26. Genomic and Molecular Analyses Identify Molecular Subtypes of Pancreatic Cancer Recurrence. Co-author DOI 10.1053/j.gastro.2021.09.022↗
  27. Histopathological tumour response scoring in resected pancreatic cancer following neoadjuvant therapy: international interobserver study (ISGPP-1). Co-author DOI 10.1093/bjs/znac350↗
  28. βIII-Tubulin is a Brake on Extrinsic Cell-Death in Pancreatic Cancer Co-author DOI 10.1101/2022.09.29.510034↗
  29. Clinical suspicion of pancreatic cancer despite negative endoscopic ultrasound-guided fine-needle aspiration biopsy. Co-author DOI 10.1111/ans.17256↗
  30. The role of staging laparoscopy in pancreatic adenocarcinoma and its effect on patients' survival. Co-author DOI 10.1186/s12957-022-02803-y↗
  31. The Right Treatment Strategy for the Right Patient: A Biomarker-Driven Approach to Neoadjuvant vs. Surgery-First Management of Resectable and Borderline Resect… Co-author DOI 10.3390/cancers14153620↗
  32. Prognostic implications of microRNA-21 overexpression in pancreatic ductal adenocarcinoma: an international multicenter study of 686 patients. Co-author PMID 36628279↗
  33. A unique urinary metabolomic signature for the detection of pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.33368↗
  34. Survival in borderline resectable and locally advanced pancreatic cancer is determined by the duration and response of neoadjuvant therapy. Co-author DOI 10.1016/j.ejso.2021.04.005↗
  35. Amsterdam International Consensus Meeting: tumor response scoring in the pathology assessment of resected pancreatic cancer after neoadjuvant therapy. Co-author DOI 10.1038/s41379-020-00683-9↗
  36. A Critical Assessment of Postneoadjuvant Therapy Pancreatic Cancer Regression Grading Schemes With a Proposal for a Novel Approach. Last author DOI 10.1097/pas.0000000000001601↗
  37. Intravital imaging technology guides FAK-mediated priming in pancreatic cancer precision medicine according to Merlin status. Co-author DOI 10.1126/sciadv.abh0363↗
  38. Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma Determine Response to SLC7A11 Inhibition. Co-author DOI 10.1158/0008-5472.can-20-2496↗
  39. ROR1 and ROR2 expression in pancreatic cancer. Co-author DOI 10.1186/s12885-021-08952-9↗
  40. Optimal Upfront Treatment in Surgically Resectable Pancreatic Cancer Candidates: A High-Volume Center Retrospective Analysis. Co-author DOI 10.3390/jcm10122700↗
  41. PSMD11, PTPRM and PTPRB as novel biomarkers of pancreatic cancer progression. Co-author DOI 10.1016/j.bbagen.2020.129682↗
  42. Pancreatic adenocarcinoma preferentially takes up and is suppressed by synthetic nanoparticles carrying apolipoprotein A-II and a lipid gemcitabine prodrug in … Co-author DOI 10.1016/j.canlet.2020.08.045↗
  43. International validation and update of the Amsterdam model for prediction of survival after pancreatoduodenectomy for pancreatic cancer. Co-author DOI 10.1016/j.ejso.2019.12.023↗
  44. Tissue biomarker panel as a surrogate marker for squamous subtype of pancreatic cancer. Co-author DOI 10.1016/j.ejso.2020.02.001↗
  45. Neoadjuvant therapy for pancreatic cancer changes the composition of the pancreatic parenchyma. Co-author DOI 10.1016/j.hpb.2020.03.007↗
  46. Evaluation of Fluorodeoxyglucose Positron Emission Tomography Scanning in the Neoadjuvant Therapy Paradigm in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000001472↗
  47. Pancreatoduodenectomy With Arterial Resection for Locally Advanced Pancreatic Cancer of the Head: A Systematic Review. Co-author DOI 10.1097/mpa.0000000000001551↗
  48. Precision Oncology in Surgery: Patient Selection for Operable Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000003143↗
  49. Biomarker panel predicts survival after resection in pancreatic ductal adenocarcinoma: A multi-institutional cohort study. Co-author DOI 10.1016/j.ejso.2018.10.050↗
  50. Understanding the Pathophysiology of Psychological Distress and Pancreatic Cancer: A Systematic Review. Co-author DOI 10.1097/mpa.0000000000001016↗

Closest collaborators

The 25 strongest of 202 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jaswinder Singh Samra · 50 shared papers, 2012–2026 · strength 5.91
  2. Anubhav Mittal · 30 shared papers, 2017–2026 · strength 4.61
  3. Sumit Sahni · 15 shared papers, 2020–2025 · strength 2.77
  4. Nick Pavlakis · 18 shared papers, 2014–2026 · strength 2.17
  5. Angela S. Y. Chou · 17 shared papers, 2012–2026 · strength 1.80
  6. Stephen John Clarke · 14 shared papers, 2014–2026 · strength 1.68
  7. Amber L. Johns · 18 shared papers, 2012–2026 · strength 1.60
  8. Christopher Bahdah Nahm · 12 shared papers, 2017–2025 · strength 1.41
  9. Sooin Byeon · 6 shared papers, 2023–2025 · strength 1.38
  10. Sarah Maloney · 8 shared papers, 2020–2025 · strength 1.32
  11. Marina Pajic · 16 shared papers, 2012–2026 · strength 1.25
  12. David Goldstein · 7 shared papers, 2013–2026 · strength 0.86
  13. Jennifer P. Morton · 7 shared papers, 2018–2026 · strength 0.85
  14. Josef Gillson · 4 shared papers, 2020–2025 · strength 0.82
  15. Joshua A. McCarroll · 5 shared papers, 2021–2026 · strength 0.79
  16. Mert Erkan · 5 shared papers, 2021–2026 · strength 0.79
  17. Koroush Shahsavar Haghighi · 5 shared papers, 2021–2026 · strength 0.79
  18. Phoebe A. Phillips · 5 shared papers, 2021–2026 · strength 0.79
  19. George Sharbeen · 5 shared papers, 2021–2026 · strength 0.79
  20. John Kokkinos · 5 shared papers, 2021–2026 · strength 0.79
  21. David Kuang-Fu Chang · 13 shared papers, 2012–2025 · strength 0.78
  22. Nigel Balfour Jamieson · 7 shared papers, 2019–2023 · strength 0.76
  23. Andrew Victor Biankin · 13 shared papers, 2012–2023 · strength 0.70
  24. Taymin du Toit‐Thompson · 3 shared papers, 2023–2025 · strength 0.69
  25. Malinda Itchins · 6 shared papers, 2017–2023 · strength 0.65

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.